세계의 DNA 치료제 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

DNA Repair Drugs Market - Scope of Report

TMR's report on the global DNA Repair Drugs Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global DNA Repair Drugs Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global DNA Repair Drugs Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the DNA Repair Drugs Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global DNA Repair Drugs Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global DNA Repair Drugs Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global DNA Repair Drugs Market.

The report delves into the competitive landscape of the global DNA Repair Drugs Market. Key players operating in the global DNA Repair Drugs Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global DNA Repair Drugs Market profiled in this report.

Key Questions Answered in Global DNA Repair Drugs Market Report:

• What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
• What are the opportunities in the global DNA Repair Drugs Market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

DNA Repair Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global DNA Repair Drugs Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global DNA Repair Drugs Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global DNA Repair Drugs.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global DNA Repair Drugs Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global DNA Repair Drugs Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Technological Advancements
• 5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
• 5.3. Pipeline Analysis
• 5.4. Regulatory Scenario by Region/Globally
• 5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global DNA Repair Drugs Market Analysis and Forecast, by Drug Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Drug Type, 2017-2031
  • 6.3.1. PARP Inhibitors
  • 6.3.2. Alkylating Agents
  • 6.3.3. Others
• 6.4. Market Attractiveness Analysis, by Drug Type

7. Global DNA Repair Drugs Market Analysis and Forecast, by Dosage Form

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 7.3.1. Breast Cancer
  • 7.3.2. Ovarian Cancer
  • 7.3.3. Lung Cancer
  • 7.3.4. Head and Neck Cancer
  • 7.3.5. Others
• 7.4. Market Attractiveness Analysis, by Dosage Form

8. Global DNA Repair Drugs Market Analysis and Forecast, by Dosage Form

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 8.3.1. Tablets
  • 8.3.2. Capsules
  • 8.3.3. Injectables
• 8.4. Market Attractiveness Analysis, by Dosage Form

9. Global DNA Repair Drugs Market Analysis and Forecast, by Distribution Channel

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 9.3.1. Retail Pharmacies
  • 9.3.2. Hospital Pharmacies
  • 9.3.3. Online Pharmacies
• 9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global DNA Repair Drugs Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region, 2017-2031
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness By Country/Region

11. North America DNA Repair Drugs Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Drug Type, 2017-2031
  • 11.2.1. PARP Inhibitors
  • 11.2.2. Alkylating Agents
  • 11.2.3. Others
• 11.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 11.3.1. Breast Cancer
  • 11.3.2. Ovarian Cancer
  • 11.3.3. Lung Cancer
  • 11.3.4. Head and Neck Cancer
  • 11.3.5. Others
• 11.4. Market Value Forecast, by Dosage Form, 2017-2031
  • 11.4.1. Tablets
  • 11.4.2. Capsules
  • 11.4.3. Injectables
• 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 11.5.1. Retail Pharmacies
  • 11.5.2. Hospital Pharmacies
  • 11.5.3. Online Pharmacies
• 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Drug Type
  • 11.7.2. By Dosage Form
  • 11.7.3. By Dosage Form
  • 11.7.4. By Distribution Channel
  • 11.7.5. By Country/Sub-region

12. Europe DNA Repair Drugs Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Drug Type, 2017-2031
  • 12.2.1. PARP Inhibitors
  • 12.2.2. Alkylating Agents
  • 12.2.3. Others
• 12.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 12.3.1. Breast Cancer
  • 12.3.2. Ovarian Cancer
  • 12.3.3. Lung Cancer
  • 12.3.4. Head and Neck Cancer
  • 12.3.5. Others
• 12.4. Market Value Forecast, by Dosage Form, 2017-2031
  • 12.4.1. Tablets
  • 12.4.2. Capsules
  • 12.4.3. Injectables
• 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.5.1. Retail Pharmacies
  • 12.5.2. Hospital Pharmacies
  • 12.5.3. Online Pharmacies
• 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Italy
  • 12.6.5. Spain
  • 12.6.6. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Drug Type
  • 12.7.2. By Dosage Form
  • 12.7.3. By Dosage Form
  • 12.7.4. By Distribution Channel
  • 12.7.5. By Country/Sub-region

13. Asia Pacific DNA Repair Drugs Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Drug Type, 2017-2031
  • 13.2.1. PARP Inhibitors
  • 13.2.2. Alkylating Agents
  • 13.2.3. Others
• 13.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 13.3.1. Breast Cancer
  • 13.3.2. Ovarian Cancer
  • 13.3.3. Lung Cancer
  • 13.3.4. Head and Neck Cancer
  • 13.3.5. Others
• 13.4. Market Value Forecast, by Dosage Form, 2017-2031
  • 13.4.1. Tablets
  • 13.4.2. Capsules
  • 13.4.3. Injectables
• 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.5.1. Retail Pharmacies
  • 13.5.2. Hospital Pharmacies
  • 13.5.3. Online Pharmacies
• 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.6.1. China
  • 13.6.2. Japan
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Drug Type
  • 13.7.2. By Dosage Form
  • 13.7.3. By Dosage Form
  • 13.7.4. By Distribution Channel
  • 13.7.5. By Country/Sub-region

14. Latin America DNA Repair Drugs Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Drug Type, 2017-2031
  • 14.2.1. PARP Inhibitors
  • 14.2.2. Alkylating Agents
  • 14.2.3. Others
• 14.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 14.3.1. Breast Cancer
  • 14.3.2. Ovarian Cancer
  • 14.3.3. Lung Cancer
  • 14.3.4. Head and Neck Cancer
  • 14.3.5. Others
• 14.4. Market Value Forecast, by Dosage Form, 2017-2031
  • 14.4.1. Tablets
  • 14.4.2. Capsules
  • 14.4.3. Injectables
• 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 14.5.1. Retail Pharmacies
  • 14.5.2. Hospital Pharmacies
  • 14.5.3. Online Pharmacies
• 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Drug Type
  • 14.7.2. By Dosage Form
  • 14.7.3. By Dosage Form
  • 14.7.4. By Distribution Channel
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa DNA Repair Drugs Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Drug Type, 2017-2031
  • 15.2.1. PARP Inhibitors
  • 15.2.2. Alkylating Agents
  • 15.2.3. Others
• 15.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 15.3.1. Breast Cancer
  • 15.3.2. Ovarian Cancer
  • 15.3.3. Lung Cancer
  • 15.3.4. Head and Neck Cancer
  • 15.3.5. Others
• 15.4. Market Value Forecast, by Dosage Form, 2017-2031
  • 15.4.1. Tablets
  • 15.4.2. Capsules
  • 15.4.3. Injectables
• 15.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 15.5.1. Retail Pharmacies
  • 15.5.2. Hospital Pharmacies
  • 15.5.3. Online Pharmacies
• 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Drug Type
  • 15.7.2. By Dosage Form
  • 15.7.3. By Application
  • 15.7.4. By Distribution Channel
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 16.2. Market Share Analysis, by Company (2021)
• 16.3. Company Profiles
  • 16.3.1. AstraZeneca plc
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Product Portfolio
    • 16.3.1.3. Financial Overview
    • 16.3.1.4. SWOT Analysis
    • 16.3.1.5. Strategic Overview
  • 16.3.2. Clovis Oncology
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Product Portfolio
    • 16.3.2.3. Financial Overview
    • 16.3.2.4. SWOT Analysis
    • 16.3.2.5. Strategic Overview
  • 16.3.3. GlaxoSmithKline plc
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Product Portfolio
    • 16.3.3.3. Financial Overview
    • 16.3.3.4. SWOT Analysis
    • 16.3.3.5. Strategic Overview
  • 16.3.4. Pfizer Inc.
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Product Portfolio
    • 16.3.4.3. Financial Overview
    • 16.3.4.4. SWOT Analysis
    • 16.3.4.5. Strategic Overview
  • 16.3.5. Merck & Co. Inc.
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Product Portfolio
    • 16.3.5.3. Financial Overview
    • 16.3.5.4. SWOT Analysis
    • 16.3.5.5. Strategic Overview
  • 16.3.6. Novartis AG
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Product Portfolio
    • 16.3.6.3. Financial Overview
    • 16.3.6.4. SWOT Analysis
    • 16.3.6.5. Strategic Overview
  • 16.3.7. Johnson & Johnson
    • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.7.2. Product Portfolio
    • 16.3.7.3. Financial Overview
    • 16.3.7.4. SWOT Analysis
    • 16.3.7.5. Strategic Overview
  • 16.3.8. Bristol Myers Squibb Company
    • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.8.2. Product Portfolio
    • 16.3.8.3. Financial Overview
    • 16.3.8.4. SWOT Analysis
    • 16.3.8.5. Strategic Overview
  • 16.3.9. Onxeo
    • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.9.2. Product Portfolio
    • 16.3.9.3. Financial Overview
    • 16.3.9.4. SWOT Analysis
    • 16.3.9.5. Strategic Overview